Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Market Insight – Courts' rulings spell confusion for brand names

This article was originally published in Scrip

Executive Summary

The branding of pharmaceuticals including, increasingly, branded generics is of huge importance to pharma companies. Vast amounts of time and money are spent in clearing new names for novel drugs (and also in clearing non-proprietary names) and protecting them through the trademark registration system in the hope that everything will be in place by the time the product is ready to launch.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC030846

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel